## APPENDIX A

Table A.1 Coverage Rates, by Vaccination Grouping and Disease

Influenza	, accuration of our	
Vaccination Grouping	Coverage Rate	Source(s)
Under 1 Year	29.9	
1-4 Years	26	
5-9 Years	17.2	
10-14 Years	14.5	
15-19 Years	12.7	
20-24 Years	11.9	
25-29 Years	14.4	
30-34 Years	18.2	
35-39 Years	20.2	
40-44 Years	20.2	
45-49 Years	21.5	
50-54 Years	25.7	
55-59 Years	31.6	(1)
60-64 Years	41.2	
65-69 Years	53.7	
70-74 Years	60.8	
75-79 Years	66.1	
80-84 Years	67.5	
85-89 Years	70.5	
90+ Years	74.5	
Unknown	0	
All Ages	26.8	
6 Months - 4 Years	29.4	
65+ Years	64.5	
Shingles		
Ages 70+	47.0%	
Ages 65+	47.0%	(2-3)
Ages 50+	27.4%	
Pneumococcal		
Age 50	22.0%	(4)
Age 65	48.3%	
Pertussis Pregnant women	60.1%	(5-7)
i regnam wollien	00.1/0	(3-1)

Table A.2 Vaccine Effectiveness by Age, Any Influenza

		, , ,			
Product	aVE (65+)	aVE (20-64)	aVE (6-19)	aVE (<6)	Source
QIV-HD	0.5105	n/a	n/a	n/a	(8; Author Assumptions)
QIV	0.3833	0.5100	0.5540	0.5540	(9-11; Author Assumptions)
aQIV	0.5309	n/a	n/a	n/a	(12; Author Assumptions)
ccQIV	0.4006	0.5336	0.5460	0.5460	(9, 12; Author Assumptions)
aTIV	0.4300	n/a	n/a	0.8600	(13, 14; Author Assumptions)

Abbreviations: QIV = quadrivalent; QIV-HD = quadrivalent high dose; aQIV = adjuvanted quadrivalent;

 $aTIV = adjuvanted \ trivalent; \ ccQIV = cell-based \ quadrivalent; \ aVE = absolute \ vaccine \ effectiveness.$ 

Table A.3 Vaccine Effectiveness, by Age and Influenza Strain

Product	aVE (65+)	aVE (20-64)	aVE (6-19)	aVE (<6)	Source
Influenza A					
QIV	H1N1 0.54 H3N2 0.33	H1N1 0.55 H3N2 0.50	0.568	0.568	(10, 11; Author Assumption)
ccQIV	n/a	n/a	0.57	0.57	(12; Author Assumption)
aTIV	H1N1 0.66 H3N2 0.40	n/a	n/a	n/a	(Author Assumption)
Influenza B					
QIV	0.31	0.45	0.495	0.495	(Author Assumption)
ccQIV	n/a	n/a	0.476	0.476	(10, 11; Author Assumption)
aTIV	0.285	n/a	n/a	n/a	(Author Assumption)

Abbreviations: QIV = quadrivalent; QIV-HD = quadrivalent high dose; aQIV = adjuvanted quadrivalent;

Table A.4 Absolute Vaccine Effectiveness, Pneumococcal

Product	Base	Source
Pneu-C (at age 65)		
VT-IPD	0.600	
ST3-IPD	0.260	(4)
VT-CAP	0.450	(4)
ST3-CAP	0.156	
Pneu-P-23 (at age 65)		
VT-IPD	0.470	
ST3-IPD	0.020	(4)
VT-CAP	0.200	(4)
ST3-CAP	0.020	
Vaccine effectiveness at age 50	1.1x effectiveness at age 65	(4)
Vaccine effectiveness at age 75	0.9x effectiveness at age 65	(4)

Abbreviations: VT = vaccine-type; IPD = invasive pneumococcal disease;

ST3 = serotype 3; CAP = community-acquired pneumonia.

aTIV = adjuvanted trivalent; ccQIV = cell-based quadrivalent; aVE = absolute vaccine effectiveness.

Table A.5 Absolute Vaccine Effectiveness, Shingles

Product	Ages 50-69	Ages 70+	Source
RZV	0.97	0.91	(16)

RZV = recombinant zoster vaccine.

Table A.6 Absolute Vaccine Effectiveness, Pertussis

Product	Infants (Maternal	Adult	
	vaccination)	Booster	Source
Tdon	0.80-0.90	0.8899	(17-21)
Tdap	0.80-0.90	0.8899	

Tdap = tetanus, diphtheria, & acellular pertussis.

**Table A.7** Full Vaccine Costs

Product	Total cost, 1 dose	Source
Tdap	\$78	(22)
RZV	\$165	(22)
QIV	\$46	(22)
QIV-HD	\$110	(23)
aQIV	\$113	(23)
aTIV	\$97	(23)
ccQIV	\$56	(22)
Pneu-P-23		(4, 24, 25; Author
	\$32	assumption)
Pneu-C-15		(4, 24, 25; Author
	\$95	assumption)
Pneu-C-20		(4, 24, 25; Author
	\$107	assumption)

Abbreviations: QIV = quadrivalent; QIV-HD = quadrivalent High Dose; aQIV = adjuvanted quadrivalent; aTIV = adjuvanted trivalent; ccQIV = cell-based quadrivalent; Pneu-C-15 = 15-valent pneumococcal conjugate; Pneu-C-20 = 20-valent pneumococcal conjugate; Pneu-P-23 = pneumococcal polysaccharide 23-valent; RZV = recombinant zoster vaccine; Tdap = tetanus, diphtheria, & acellular pertussis.

## References for Appendix A

- 1. Government of Alberta. Alberta influenza statistics [Internet]. Date published: 2022. Accessed November 21, 2023. Available from https://web.archive.org/web/20220621171159/https://www.alberta.ca/stats/influenza/statistics.htm#highlights.
- 2. Public Health Agency of Canada. Vaccine uptake in Canadian adults 2021 [Internet]. Date published: March 25, 2022. Accessed November 21, 2023. Available from https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/highlights-2020-2021-seasonal-influenza-survey/full-report.html.
- 3. CanAge. Adult vaccination in Canada cross-country report card 2021 [Internet]. Date published: February 2, 2021. Accessed November 21, 2023. Available from https://www.canada.ca/en/public-health/services/immunization-vaccines/vaccination-coverage/highlights-2020-2021-seasonal-influenza-survey/full-report.html.
- 4. National Advisory Committee on Immunization. Recommendations on the use of conjugate pneumococcal vaccine 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults:

- Economic evidence supplementary appendix [Internet]. Date published: 2023-02-24. Accessed November 21, 2023 Available from https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html.
- 5. Public Health Agency of Canada. Results of the survey on vaccination during pregnancy 2021 [Internet]. Date published: December 13, 2022. Accessed November 21, 2023. Available from https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/survey-vaccination-during-pregnancy-2021.html#t1.
- 6. Public Health Agency of Canada. Vaccine uptake in canadian adults results from the 2016 adult national immunization coverage survey (anics) [Internet]. Date published: July, 2018. Accessed November 21, 2023. Available from https://publications.gc.ca/collections/collection\_2018/aspc-phac/HP40-222-2018-eng.pdf.
- 7. Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, national health interview survey, 2019–2020 [Internet]. Date published: February 17, 2022. Accessed November 21, 2023. Available from https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccination-coverage-adults-2019-2020.html.
- 8. Lee, J. K. H., G. K. L. Lam, T. Shin, S. I. Samson, D. P. Greenberg, and A. Chit. "Efficacy and Effectiveness of High-Dose Influenza Vaccine in Older Adults by Circulating Strain and Antigenic Match: An Updated Systematic Review and Meta-Analysis." *Vaccine* 39 Suppl 1 (Mar 15 2021): A24-A35. DOI:10.1016/j.vaccine.2020.09.004.
- 9. National Centre for Immunization and Respiratory Diseases. Influenza vaccines for older adults [Internet]. Date published: January 12, 2022. Accessed November 21, 2023. Available from https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-01-12/02-inlfuenza-grohskopf-508.pdf.
- 10. Rondy M, El Omeiri N, Thompson MG, Leveque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. *J Infect* 2017;75(5):381-94. DOI: 10.1016/j.jinf.2017.09.010
- 11. Jain VK, Rivera L, Zaman K, Espos RA, Jr., Sirivichayakul C, Quiambao BP, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. *N Engl J Med* 2013;369(26):2481-91. DOI:10.1056/NEJMoa1215817.
- 12. Ruiz-Aragon J, Marquez-Pelaez S, Gani R, Alvarez P, Guerrero-Luduena R. Cost-effectiveness and burden of disease for adjuvanted quadrivalent influenza vaccines compared to high-dose quadrivalent influenza vaccines in elderly patients in spain. *Vaccines (Basel)* 2022;10(2). DOI: 10.3390/vaccines10020176.
- 13. Nolan T, Fortanier AC, Leav B, Poder A, Bravo LC, Szymanski HT, et al. Efficacy of a cell-culture-derived quadrivalent influenza vaccine in children. *N Engl J Med* 2021;385(16):1485-95. DOI: 10.1056/NEJMoa2024848.
- 14. E OM, Comber L, Jordan K, Hawkshaw S, Marshall L, O'Neill M, et al. Systematic review of the efficacy, effectiveness and safety of mf59((R)) adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals >/=18 years of age. *Rev Med Virol* 2023;33(3):e2329. DOI: 10.1002/rmv.2329.

- 15. Public Health Agency of Canada. An advisory committee statement (ACS) national advisory committee on immunization (NACI) literature review on pediatric fluad® influenza vaccine use in children 6-72 months of age [Internet]. Date published: October 2, 2015. Accessed November 21, 2023. Available from https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/literature-review-on-pediatric-fluad-influenza-vaccine-use-children-6-72-months.html.
- 16. Centers for Disease Control and Prevention. Shingles vaccination: What everyone should know [Internet]. Date published: May 8, 2023. Accessed November 21, 2023. Available from https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix/index.html.
- 17. Xu J, Liu S, Liu Q, Rong R, Tang W, Wang Q, et al. The effectiveness and safety of pertussis booster vaccination for adolescents and adults: A systematic review and meta-analysis. *Medicine* (*Baltimore*) 2019;98(16):e15281. DOI: 10.1097/MD.000000000015281.
- 18. Vygen-Bonnet S, Hellenbrand W, Garbe E, von Kries R, Bogdan C, Heininger U, et al. Safety and effectiveness of acellular pertussis vaccination during pregnancy: A systematic review. *BMC Infect Dis* 2020;20(1):136. DOI: 10.1186/s12879-020-4824-3.
- 19. Fernandes EG, Sato APS, Vaz-de-Lima LRA, Rodrigues M, Leite D, de Brito CA, et al. The effectiveness of maternal pertussis vaccination in protecting newborn infants in brazil: A case-control study. *Vaccine* 2019;37(36):5481-4. DOI: 10.1016/j.vaccine.2019.03.049.
- 20. Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. *Clin Infect Dis* 2017;64(1):3-8. DOI: 10.1093/cid/ciw634.
- 21. Romanin V, Acosta AM, Juarez MDV, Briere E, Sanchez SM, Cordoba BL, et al. Maternal vaccination in argentina: Tetanus, diphtheria, and acellular pertussis vaccine effectiveness during pregnancy in preventing pertussis in infants <2 months of age. *Clin Infect Dis* 2020;70(3):380-7. DOI: 10.1093/cid/ciz217.
- 22. Centers for Disease Control and Prevention. CDC Vaccine Price List [Internet]. Accessed November 21, 2023. Available from https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html.
- 23. Centers for Medicare and Medicaid Services. Vaccine pricing [Internet]. Accessed November 21, 2023. Available from https://www.cms.gov/medicare/payment/part-b-drugs/vaccine-pricing.
- 24. Atwood, M., L. Beausoleil, M. C. Breton, C. Laferriere, R. Sato, and D. Weycker. "Cost-Effectiveness of Alternative Strategies for Use of 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) in Canadian Adults." *Can J Public Health* 109, no. 5-6 (Dec 2018): 756-68. DOI:10.17269/s41997-018-0050-9.
- 25. Crawley A, Bareham J. VACCINES: Pneumococcal, Influenza, & Shingles [Internet]. Accessed November 21, 2023. Available from https://www.rxfiles.ca/RxFiles/uploads/documents/Vaccines-Pneumococcal-%20Influenza-%20Shingles%20Q%20and%20A.pdf.

## APPENDIX B

Table B.1 Vaccine Portfolio Selections, Full Vaccine Cost Scenario, CAN\$500M Budget

	_		Size of I	mmunization Portfolio	
		One Program	Two Programs	Three Programs	Four Programs
II141 D£4	HM	3,890.13	5,650.41	6,759.50	7,169.39
Health Benefit (QALYs Gained)	INMB \$50,000/QALY \$30,000/QALY	1,193.89 1,193.89	1,412.68 1,412.68	Not feasible  Not feasible	Not feasible Not feasible
	HM	83.06%	99.78%	93.67%	97.50%
Percentage of Budget Used	INMB \$50,000/QALY \$30,000/QALY	4.45% 4.45%	5.67% 5.67%	Not feasible Not feasible	Not feasible Not feasible
	НМ	ccQIV for ages 18-64	RZV for ages 65+ (57% coverage) <b>AND</b> QIV for 18-64	Maternal Tdap (75% coverage)  AND  RZV for ages 50+ (37% coverage) AND  QIV for 65+	Maternal Tdap (75% coverage)  AND  RZV for ages 50+ (37% coverage)  AND  QIV for 65+ AND  Pneu-C-20 & Pneu-P-23 at age 50 (22% coverage)
Vaccine Program(s) Selected	INMB \$50,000/QALY	Maternal Tdap (50% coverage)	Maternal Tdap (50% coverage) AND Pneu-P-23 at age 50 (22% coverage)	Not feasible	Not feasible
	\$30,000/QALY	Maternal Tdap (50% coverage)	Maternal Tdap (50% coverage)  AND Pneu-P-23 at age 50 (22% coverage)	Not feasible	Not feasible

Abbreviations: HM, health-maximizing; INMB, incremental net monetary benefit; QALY, quality-adjusted life year; QIV = quadrivalent; ccQIV = cell-based quadrivalent; Pneu-C-20 = 20-valent pneumococcal conjugate; Pneu-P-23 = pneumococcal polysaccharide 23-valent; RZV = recombinant zoster vaccine; Tdap = tetanus, diphtheria, & acellular pertussis.

**Table B.2** Vaccine Portfolio Selections, Main Scenario, CAN\$500M Budget and CAN\$100,000/QALY Threshold

	_	Size of Immunization Portfolio				
		One Program	Two Programs	Three Programs	Four Programs	
Health Benefit (QALYs Gained)	INMB \$100,000/QALY	6,112.60	8,136.60	9,400.28	9,549.28	
Percentage of Budget Used	INMB \$100,000/QALY	80.39%	95.70%	99.74%	99.25%	
Vaccine Program(s) Selected	INMB \$100,000/QALY	OIV for 18+	RZV for ages 65+ (57% coverage) AND OIV for ages 18+	Maternal Tdap (75% coverage)  AND  RZV for ages 65+ (57% coverage) AND  OIV for ages 18+	Maternal Tdap (50% coverage)  AND RZV for ages 65+ (57% coverage)  AND QIV for ages 18+ AND Pneu-P  23 at age 50 (22% coverage)	

Abbreviations: INMB, incremental net monetary benefit; QALY, quality-adjusted life year; QIV = quadrivalent; Pneu-P-23 = pneumococcal polysaccharide 23-valent; RZV = recombinant zoster vaccine; Tdap = tetanus, diphtheria, & acellular pertussis.

Table B.3 Vaccine Portfolio Selections, Main Scenario, CAN\$100M Budget

		Size of Immunization Portfolio					
		One Program	Two Programs	Three Programs	Four Programs		
II 14 D	HM	2,024.00	3,287.68	3,572.59	Not feasible		
Health Benefit (QALYs	INMB \$50,000/QALY	1,193.89	3,217.89	3,572.59	Not feasible		
gained)	\$30,000/QALY	1,193.89	3,217.89	3,572.59	Not feasible		
	HM	76.55%	96.79%	98.64%	Not feasible		
Percentage of Budget Used	INMB \$50,000/QALY	13.49%	90.04%	98.64%	Not feasible		
	\$30,000/QALY	13.49%	90.04%	98.64%	Not feasible		
	НМ	RZV for age 65+ (57% coverage)	Maternal Tdap (75% coverage) AND RZV for ages 65+ (57% coverage)	Maternal Tdap (50% coverage)  AND  RZV for ages 65+ (57% coverage)  AND  Pneu-C-20 at age 50 (22% coverage)	Not Feasible		
Vaccine Program(s)	INMB		Maternal Tdap (50% coverage) AND	Maternal Tdap (50% coverage)  AND  RZV for ages 65+ (57% coverage)			
Selected	\$50,000/QALY	Maternal Tdap (50% coverage)	RZV for ages 65+ (57% coverage) Maternal Tdap (50%	AND Pneu-C-20 at age 50 (22% coverage) Maternal Tdap (50% coverage)	Not Feasible		
	\$30,000/QALY	Maternal Tdap (50% coverage)	coverage) AND RZV for ages 65+ (57% coverage)	AND RZV for ages 65+ (57% coverage) AND Pneu-C-20 at age 50 (22% coverage)	Not Feasible		

Abbreviations: HM, health-maximizing; INMB, incremental net monetary benefit; QALY, quality-adjusted life year; Pneu-C-20 = 20-valent pneumococcal conjugate; RZV = recombinant zoster vaccine; Tdap = tetanus, diphtheria, & acellular pertussis.

Table B.4 Vaccine Portfolio Selections, Main Scenario, CAN\$1B Budget

			Size of	Immunization Portfolio	
		One Program	Two Programs	Three Programs	Four Programs
H 14 D 6.	HM	7,070.02	9,679.34	10,943.01	11,352.90
Health Benefit (QALYs Gained)	INMB \$50,000/QALY	2,609.32	3,803.21	7,429.62	7,839.51
,	\$30,000/QALY	1,193.89	3,217.89	3,572.59	Not feasible
Percentage of	HM	55.42%	65.68%	67.70%	68.90%
Budget Used	INMB \$50,000/QALY	10.25%	11.60%	35.33%	36.53%
	\$30,000/QALY	1.35%	9.00%	9.86%	Not feasible
Vaccine	НМ	ccQIV for 18-64 and aQIV for 65+	ccQIV for 18-64 and aQIV for 65+ AND RZV for ages 50+ (37% coverage)	Maternal Tdap (75% coverage)  AND  ccQIV for 18-64 and aQIV for 65+  AND  RZV for ages 50+ (37% coverage)	Maternal Tdap (75% coverage) AND ccQIV for 18-64 and aQIV for 65+ AND RZV for ages 50+ (37% coverage) AND Pneu-C-20 & Pneu-P-23 at age 50 (22% coverage)
Program(s) Selected	INMB \$50,000/QALY	RZV for ages 50+ (37% coverage)	Maternal Tdap (50% coverage) AND RZV for ages 50+ (37% coverage)	Maternal Tdap (50% coverage) AND QIV for ages 18-64 AND RZV for ages 50+ (37% coverage)	Maternal Tdap (50% coverage)  AND  QIV for ages 18-64  AND  RZV for ages 50+ (37% coverage)  AND  Pneu-C-20 & Pneu-P-23 at age 50 (22% coverage)
	\$30,000/QALY	Maternal Tdap (50% coverage)	Maternal Tdap (50% coverage) AND RZV for ages 65+ (57% coverage)	Maternal Tdap (50% coverage)  AND  RZV for ages 65+ (57% coverage)  AND  Pneu-C-20 at age 50 (22% coverage)	Not Feasible

Abbreviations: HM, health-maximizing; INMB, incremental net monetary benefit; QALY, quality-adjusted life year; aQIV = adjuvanted quadrivalent; QIV = quadrivalent; ccQIV = cell-based quadrivalent; Pneu-C-20 = 20-valent pneumococcal conjugate; Pneu-P-23 = pneumococcal polysaccharide 23-valent; RZV = recombinant zoster vaccine; Tdap = tetanus, diphtheria, & acellular pertussis.

Figure B.5 Scenario with Full Vaccine Costs and CAN\$30,000/QALY Threshold, Incremental Net Monetary Benefit Optimization




Figure B.6 Scenario with Full Vaccine Costs and CAN\$50,000/QALY Threshold, Incremental Net Monetary Benefit Optimization




Figure B.7 Scenario with Full Vaccine Costs and CAN\$100,000/QALY Threshold, Incremental Net Monetary Benefit Optimization




Figure B.8 Scenario with Full Vaccine Costs, Health-maximizing Optimization

